PIMR and Pulmonary Vascular Disease

Last updated: December 3, 2024
Sponsor: University of California, Los Angeles
Overall Status: Completed

Phase

N/A

Condition

Pulmonary Arterial Hypertension

High Blood Pressure (Hypertension)

Stress

Treatment

Pulmonary Index of Microcirculatory Resistance

Right Ventricle Index of Microcirculatory Resistance

Pulmonary artery OCT

Clinical Study ID

NCT05843461
IRB#22-001643
  • Ages > 18
  • All Genders

Study Summary

The findings from this innovative, first-in-man, prospective pilot study will elucidate the role of PIMR and RV-IMR in pre-capillary PH. The study cohort will consist of patients with pulmonary pressures ranging from normal (advanced lung disease patients undergoing lung transplant evaluation) to severe PH (PAH and CTEPH patients), and thus will allow for identification of a PIMR cutoff. Participants will include: 1) advanced lung disease patients undergoing bilateral heart catheterization as part of their pre-lung transplant work-up, and 2) newly referred patients to PAH and CTEPH clinics undergoing bilateral heart catheterization as part of standard of care work-up. All participants will undergo PIMR testing, and those with pre-capillary PH will also undergo pulmonary OCT and measurement of RV-IMR. The study seeks to define the relationship between PIMR and PH and to establish the PIMR threshold that identifies pulmonary microvascular dysfunction as well as to evaluate the association of PIMR and pulmonary vascular remodeling on OCT in patients with pre-capillary PH. In addition, the study will assess the relationship between RV-IMR and RV pressure overload among patients with pre-capillary PH.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • ≥18 years old

  • Able to provide informed written consent.

  • Patients with 1) advanced lung disease requiring standard-of-care bilateral heartcatheterization as part of lung transplant evaluation in whom mPAP < 20 mmHg on RHC,or 2) PAH/CTEPH (i.e. pre-capillary PH) undergoing standard-of-care bilateral heartcatheterization as part of their work-up/treatment

Exclusion

Exclusion Criteria:

  • Contraindicated to undergo fluoroscopy and/or coronary angiography (e.g. pregnancy)

  • Chronic kidney disease (serum creatinine ≥ 2.0 mg/dL)

Study Design

Total Participants: 30
Treatment Group(s): 3
Primary Treatment: Pulmonary Index of Microcirculatory Resistance
Phase:
Study Start date:
January 10, 2023
Estimated Completion Date:
July 31, 2024

Connect with a study center

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California 90095
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.